Group 1 - Nanyang City has launched an action plan to develop a biomanufacturing pilot zone, focusing on project traction, platform construction, and element guarantee to accelerate the transformation and industrial application of scientific research achievements [1] - The Henan Qianmu Biopharmaceutical Project, jointly invested by Qianhong Pharmaceutical and Muyuan Group, has been put into production, filling the gap in high-end heparin raw materials in Henan Province and integrating Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang has 46 biopharmaceutical enterprises above designated size, with an estimated total industry chain output value of approximately 40 billion yuan in 2024, and 25 provincial-level innovation platforms, supporting a full chain from R&D to pilot testing to industrialization [1] Group 2 - Nanyang is actively developing synthetic biology, leveraging the talent and technological advantages of the Nanyang Synthetic Biology Research Institute to create a new generation of efficient, low-consumption, and green bioprocessing platforms [1] - The city is focusing on the industrialization of high-efficiency biosynthesis projects for essential amino acids and microbial synthesis of oils, as well as the development of high-end bio-based materials and new food products like "artificial protein" [1] - The construction of strategic leading laboratories is being strengthened, with the first technology transfer project from the Nanyang pilot base entering mass production, expected to generate an annual output value of about 240 million yuan [2] Group 3 - Nanyang has established a technology innovation system that integrates production, education, research, and application, relying on key research platforms like Muyuan Laboratory and local universities [2] - The city has formed a favorable development pattern characterized by leading enterprises, chain-driven growth, strong product R&D capabilities, and wide market coverage in the biomanufacturing industry [2]

Group 1 - The core viewpoint of the article is that Nanyang City is actively developing a biomanufacturing industry by implementing an action plan that focuses on project traction, platform construction, and element guarantee to transform research achievements into industrial applications [1][2] - The establishment of the Henan Qianmu Biopharmaceutical project, a joint investment by Qianhong Pharmaceutical and Muyuan Group, fills the gap in high-end heparin raw materials in Henan Province and integrates Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang currently has 46 biopharmaceutical enterprises above designated size, with an expected total industry chain output value of approximately 40 billion yuan in 2024 [1] Group 2 - Nanyang is enhancing its strategic laboratory construction, with the Muyuan Laboratory's "one center, one base" development model and the Zhengzhou R&D center operating in an orderly manner [2] - The first technology transfer project from Nanyang's pilot base, the "Muyuan Anliang Isolucine Project," is expected to achieve an annual output value of about 240 million yuan [2] - The city is building a technology innovation system that integrates production, education, research, and application, leveraging the advantages of key research platforms and local universities [2]